- Home
- GILD vs ORCL Comparison
GILD vs ORCL Comparison
Compare GILD & ORCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GILD | ORCL |
|---|---|---|
| Founded | 1987 | 1977 |
| Country | United States | United States |
| Employees | 17000 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 155.3B | 554.9B |
| IPO Year | 2003 | 2005 |
Fundamental Metrics
Financial Performance| Metric | GILD | ORCL |
|---|---|---|
| Price | $125.63 | $156.26 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 18 | 36 |
| Target Price | $148.39 | ★ $260.11 |
| AVG Volume (30 Days) | 7.6M | ★ 22.5M |
| Earning Date | 05-07-2026 | 06-10-2026 |
| Dividend Yield | ★ 2.55% | 1.22% |
| EPS Growth | ★ 1684.21 | 34.33 |
| EPS | 1.61 | ★ 5.83 |
| Revenue | $24,689,000,000.00 | ★ $67,357,000,000.00 |
| Revenue This Year | $4.68 | $19.50 |
| Revenue Next Year | $6.04 | $31.91 |
| P/E Ratio | $77.67 | ★ $28.34 |
| Revenue Growth | 9.98 | ★ 17.35 |
| 52 Week Low | $107.75 | $134.57 |
| 52 Week High | $157.29 | $345.72 |
Technical Indicators
Market Signals| Indicator | GILD | ORCL |
|---|---|---|
| Relative Strength Index (RSI) | 43.53 | 32.30 |
| Support Level | $116.55 | $136.34 |
| Resistance Level | $126.46 | $166.83 |
| Average True Range (ATR) | 3.48 | 11.77 |
| MACD | 0.05 | -6.46 |
| Stochastic Oscillator | 39.82 | 1.57 |
Price Performance
Historical ComparisonAbout GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
About ORCL Oracle Corporation
Oracle provides enterprise applications and infrastructure offerings through a variety of flexible IT deployment models, including on-premises, cloud-based, and hybrid. Founded in 1977, Oracle pioneered the first commercial SQL-based relational database management system, which is commonly used by the world's largest companies for high-volume online transaction processing workloads. Besides databases, Oracle also sells enterprise resource planning platforms and cloud infrastructure that play an increasingly important role in large language model training and inferencing.